Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

Biography

<< Back

Sherwin Sattarzadeh

Senior Vice President, Strategic Operations

Sherwin is a seasoned business leader with over 20 years of experience in the biotechnology and pharmaceutical industry. He has served as the Senior Vice President of Strategic Operations at Blueprint Medicines since January 2022, previously serving in leadership roles including as the Chief of Staff of the CEO and COO and Head of Regulatory Affairs since joining the company in 2015. Sherwin has a proven track record in drug development and business operations across multiple therapeutic areas. A member of the Blueprint Executive Team and various governance teams, he excels in building and leading teams, developing and executing program, portfolio and corporate strategies, and resolving complex business issues. Recently, he led and contributed to portfolio strategy, business development and alliance management priorities, including the post-acquisition integration of Lengo Therapeutics and the sale of Gavreto (pralsetinib) to Rigel Pharmaceuticals. Prior to joining Blueprint Medicines, Sherwin held various leadership positions in the oncology and rare disease business units at Genzyme, a Sanofi Company. During his career, he has led registration programs resulting in US and global approvals of multiple medicines, including Ayvakit (avapritinib), Gavreto (pralsetinib), Cerdelga (eliglustat), and Mozobil (plerixafor). Sherwin received a BSc in Organic Chemistry from the University of British Columbia and an MBA from Boston University's Questrom School of Business.